Evidence map›Paper›PMID 19763139›Full record

ReviewCell death and differentiation2010

Adenosine signaling and function in glial cells.

D Boison, J-F Chen, B B Fredholm

Open access · hybridAbstract readReview
In one paragraph

Review in Cell death and differentiation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed
11.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 304 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Dual CD73/AFrontiers in pharmacology · 2026
    Article
  7. Review
  8. Review
  9. Adenosine AJournal of the American Heart Association · 2025
    Article
  10. Targeting adenosine APurinergic signalling · 2025
    Review
  11. Review
  12. Astrocytes Regulate Brain State Transitions.Neurochemical research · 2025
    Review
  13. Review
  14. Adenosine Kinase: An Epigenetic Modulator and Drug Target.Journal of inherited metabolic disease · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Neuroglia and brain energy metabolism.Handbook of clinical neurology · 2025
    Review
  19. Article
  20. Article

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

D BoisonRobert Stone Dow Neurobiology Laboratories, Legacy Research, Portland, OR 97232, USA. dboison@downeurobiology.org
J-F Chen
B B Fredholm
Boston University · USKarolinska Institutet · SELegacy Health · US

Funding

NOVEL BENEFIT OF A2A RECEPTOR INACTIVATION IN PD MODELSR01NS041083 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI CHEN, JIANG-FAN · 2001 to 2013
$3.1M
Adenosine and schizophrenia: mechanisms and therapiesR01MH083973 · NIMH · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2009 to 2015
$2.5M
CRCNS-Bioinformatics &ident.:cis-elements: DA receptorsR01DA019362 · NIDA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHEN, JIANG-FAN · 2004 to 2008
$1.8M
A1/A2A Receptors and Caffeine PsychostimulationR01NS048995 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHEN, JIANG-FAN · 2005 to 2009
$1.6M
Astrocyte dysfunction in epileptogenesis: the role of adenosineR01NS061844 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2009 to 2013
$1.5M
Adenosine-releasing brain implants for epilepsy therapyR01NS058780 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2008 to 2011
$1.2M
Adenosine kinase as novel therapeutic target to prevent acquired epilepsyR21NS057475 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2008 to 2009
$379k
Adenosine kinase as therapeutic target to induce and maintain ischemic toleranceR21NS057538 · NINDS · LEGACY EMANUEL HOSPITAL AND HEALTH CENTER · PI BOISON, DETLEV · 2008 to 2009
$379k
NIDA NIH HHS DA19362NIDA NIH HHS R01 DA019362NIMH NIH HHS MH083973NIMH NIH HHS R01 MH083973NINDS NIH HHS NS057475NINDS NIH HHS NS057538NINDS NIH HHS NS058780NINDS NIH HHS NS061844NINDS NIH HHS NS41083NINDS NIH HHS NS48995NINDS NIH HHS R01 NS041083NINDS NIH HHS R01 NS048995NINDS NIH HHS R01 NS058780NINDS NIH HHS R01 NS061844NINDS NIH HHS R21 NS057475NINDS NIH HHS R21 NS057538
6 · The paper itself

Abstract

Despite major advances in a variety of neuroscientific research fields, the majority of neurodegenerative and neurological diseases are poorly controlled by currently available drugs, which are largely based on a neurocentric drug design. Research from the past 5 years has established a central role of glia to determine how neurons function and, consequently, glial dysfunction is implicated in almost every neurodegenerative and neurological disease. Glial cells are key regulators of the brain's endogenous neuroprotectant and anticonvulsant adenosine. This review will summarize how glial cells contribute to adenosine homeostasis and how glial adenosine receptors affect glial function. We will then move on to discuss how glial cells interact with neurons and the vasculature, and outline new methods to study glial function. We will discuss how glial control of adenosine function affects neuronal cell death, and its implications for epilepsy, traumatic brain injury, ischemia, and Parkinson's disease. Eventually, glial adenosine-modulating drug targets might be an attractive alternative for the treatment of neurodegenerative diseases. There are, however, several major open questions that remain to be tackled.

Indexed as

AdenosineAnticonvulsantsApoptosisHumansNeurodegenerative DiseasesNeurogliaNeuronsReceptors, Purinergic P1Signal TransductionAdenosineAnticonvulsantsReceptors, Purinergic P1

Identifiers

PMID19763139
PMCPMC2885470
OpenAlexW2094384373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.